SwePub
Sök i SwePub databas

  Utökad sökning

Träfflista för sökning "WFRF:(Wiklund Fredrik) "

Sökning: WFRF:(Wiklund Fredrik)

Sortera/gruppera träfflistan
   
NumreringReferensOmslagsbildHitta
1.
  • Rajan, P, et al. (författare)
  • Oncologic Outcomes After Robot-assisted Radical Prostatectomy: A Large European Single-centre Cohort with Median 10-Year Follow-up.
  • 2018
  • Ingår i: European urology focus. - 2405-4569. ; 4:3, s. 351-359
  • Tidskriftsartikel (refereegranskat)abstract
    • Robot-assisted radical prostatectomy (RARP) for prostate cancer (PCa) treatment has been widely adopted with limited evidence for long-term (>5 yr) oncologic efficacy.To evaluate long-term oncologic outcomes following RARP.Prospective cohort study of 885 patients who underwent RARP as monotherapy for PCa between 2002 and 2006 in a single European centre and followed up until 2016.RARP as monotherapy.Biochemical recurrence (BCR)-free survival (BCRFS), salvage therapy (ST)-free survival (STFS), prostate cancer-specific survival (CSS), and overall survival (OS) were estimated using the Kaplan-Meier method, and event-time distributions were compared using the log-rank test. Variables predictive of BCR and ST were identified using Cox proportional hazards models.We identified 167 BCRs, 110 STs, 16 PCa-related deaths, and 51 deaths from other/unknown causes. BCRFS, STFS, CSS, and OS rates were 81.8%, 87.5%, 98.5%, and 93.0%, respectively, at median follow-up of 10.5 yr. On multivariable analysis, the strongest independent predictors of both BCR and ST were preoperative Gleason score, pathological T stage, positive surgical margins (PSMs), and preoperative prostate-specific antigen. PSM >3mm/multifocal but not ≤3mm independently affected the risk of both BCR and ST. Study limitations include a lack of centralised histopathologic reporting, lymph node and post-operative tumour volume data in a historical cohort, and patient-reported outcomes.RARP appears to confer effective long-term oncologic efficacy. The risk of BCR or ST is unaffected by ≤3mm PSM, but further follow-up is required to determine any impact on CSS.Robot-assisted surgery for prostate cancer is effective 10 yr after treatment. Very small (<3mm) amounts of cancer at the cut edge of the prostate do not appear to impact on recurrence risk and the need for additional treatment, but it is not yet known whether this affects the risk of death from prostate cancer.
  •  
2.
  • Schwenk, Jochen M., et al. (författare)
  • Toward Next Generation Plasma Profiling via Heat-induced Epitope Retrieval and Array-based Assays
  • 2010
  • Ingår i: Molecular & Cellular Proteomics. - American Society for Biochemistry and Molecular Biology. - 1535-9484. ; 9:11, s. 2497-2507
  • Tidskriftsartikel (refereegranskat)abstract
    • There is a need for high throughput methods for screening patient samples in the quest for potential biomarkers for diagnostics and patient care. Here, we used a combination of undirected target selection, antibody suspension bead arrays, and heat-induced epitope retrieval to allow for protein profiling of human plasma in a novel and systematic manner. Several antibodies were found to reveal altered protein profiles upon epitope retrieval at elevated temperatures with limits of detection improving into lower ng/ml ranges. In a study based on prostate cancer patients, several proteins with differential profiles were discovered and subsequently validated in an independent cohort. For one of the potential biomarkers, the human carnosine dipeptidase 1 protein (CNDP1), the differences were determined to be related to the glycosylation status of the targeted protein. The study shows a path of pursuit for large scale screening of biobank repositories in a flexible and proteome-wide fashion by utilizing heat-induced epitope retrieval and using an antibody suspension bead array format. Molecular & Cellular Proteomics 9:2497-2507, 2010.
3.
  • Alexeyev, Oleg, et al. (författare)
  • Association between the presence of bacterial 16S RNA in prostate specimens taken during transurethral resection of prostate and subsequent risk of prostate cancer (Sweden)
  • 2006
  • Ingår i: Cancer Causes and Control. - Dordrecht : Kluwer Academic Publishers. - 0957-5243 .- 1573-7225. ; 17:9, s. 1127-1133
  • Tidskriftsartikel (refereegranskat)abstract
    • <p><strong>Objective</strong>: To study bacterial 16S RNA in archival prostate samples from 352 patients with benign prostate hyperplasia (BPH) and evaluate whether the presence of bacterial DNA was different in those who later developed prostate cancer (<em>n</em> = 171) and in the matched controls that did not progress to cancer (<em>n</em> = 181).</p><p><strong>Methods</strong>: 16S DNA PCR followed by cloning and sequencing the positive samples.</p><p><strong>Results</strong>: In 96/352 (27%) of the prostate tissue specimens 16S RNA were detected. Sequence analysis revealed <em>Propionibacterium acnes</em> as the predominant microorganism (23% of 16S RNA positive patients). The second most frequent isolate—<em>Escherichia coli</em> was found in 12 (12%) patients. The other isolates included <em>Pseudomonas</em> sp. (3 patients), <em>Actinomyces</em> sp. (2), <em>Streptococcus mutans</em> (1), <em>Corynebacterium</em> sp. (2),<em>Nocardioides</em> sp. (1), <em>Rhodococcus</em> sp. (1) <em>Veillonella</em> sp. (2). In <em>P. acnes</em> positive samples 62% exhibited severe histological inflammation versus 50% in the bacteria-negative group (<em>p</em> = 0.602). The presence of <em>P. acnes</em> in the prostate was associated with prostate cancer development (OR 2.17, 95% CI 0.77–6.95).</p><p><strong>Conclusions</strong>: This study has revealed <em>P. acnes</em> as the most common bacteria in the prostate in BPH. Further studies are needed to clarify its role in contributing to the development of prostatic inflammation and prostate cancer.</p>
  •  
4.
  • Bergh, Jonas, et al. (författare)
  • FACT: An Open-Label Randomized Phase III Study of Fulvestrant and Anastrozole in Combination Compared With Anastrozole Alone as First-Line Therapy for Patients With Receptor-Positive Postmenopausal Breast Cancer.
  • 2012
  • Ingår i: Journal of Clinical Oncology. - American Society of Clinical Oncology. - 1527-7755. ; 30:16, s. 1919-1925
  • Tidskriftsartikel (refereegranskat)abstract
    • PURPOSE To compare the effect of therapy with anastrozole versus a combination of fulvestrant and anastrozole in women in first relapse of endocrine-responsive breast cancer. PATIENTS AND METHODS Postmenopausal women, or premenopausal women receiving a gonadotropin-releasing hormone agonist, with estrogen receptor- and/or progesterone receptor-positive disease at first relapse after primary treatment of localized disease were open-label randomly assigned to a fulvestrant loading dose (LD) regimen followed by monthly injection plus 1 mg of anastrozole daily or to 1 mg of anastrozole daily alone. The primary end point was time to progression (TTP). RESULTS: 63 patients (24.6%) versus 35 patients (13.8%) in the standard arm (P = .0023). Death owing to AEs was reported in 11 (4.3%) and five patients (2.0%) in the experimental versus standard arm, respectively. CONCLUSION Fulvestrant (250 mg + LD regimen) in combination with anastrozole offered no clinical efficacy advantage over anastrozole monotherapy in this population of individuals with a relatively high proportion of previous adjuvant antiestrogen exposure.
  •  
5.
  • Bergh, Johanna, et al. (författare)
  • No link between viral findings in the prostate and subsequent cancer development
  • 2007
  • Ingår i: British Journal of Cancer. - London : Nature Publishing Group. - 0007-0920 .- 1532-1827. ; 96:1, s. 137-139
  • Tidskriftsartikel (refereegranskat)abstract
    • <p>In an investigation of 201 prostate tissue samples from patients with benign prostate hyperplasia that later progressed to prostate cancer and 201 matched controls that did not, there were no differences in the prevalence of adenovirus, herpesvirus, papilloma virus, polyoma virus and Candida albicans DNA.</p>
  •  
6.
  • Bonn, Stephanie E, et al. (författare)
  • Body mass index and weight change in men with prostate cancer: progression and mortality.
  • 2014
  • Ingår i: Cancer causes & control : CCC. - 1573-7225. ; 25:8, s. 933-94
  • Tidskriftsartikel (refereegranskat)abstract
    • Body mass index (BMI) is a modifiable lifestyle factor that has been associated with an increased risk of fatal prostate cancer and biochemical recurrence. The main purpose of the present study was to investigate the association between the exposure BMI at the time of a prostate cancer diagnosis and weight change after diagnosis, and the outcomes of prostate cancer progression and mortality in a large cohort study.
  •  
7.
  • Brown, David A, et al. (författare)
  • Macrophage inhibitory cytokine 1 : a new prognostic marker in prostate cancer.
  • 2009
  • Ingår i: Clinical Cancer Research. - 1078-0432 .- 1557-3265. ; 15:21, s. 6658-6664
  • Tidskriftsartikel (refereegranskat)abstract
    • <p>PURPOSE: High serum levels of macrophage inhibitory cytokine 1 (MIC-1) are strongly associated with metastatic prostate cancer, suggesting MIC-1 is a biomarker for prostate cancer prognosis. EXPERIMENTAL DESIGN: We conducted a prospective cohort study of 1,442 Swedish men with a pathologically verified diagnosis of prostate cancer between 2001 and 2003. Blood was drawn either pretreatment (n = 431) or posttreatment (n = 1,011) and cases were followed for a mean time of 4.9 years (range, 0.1-6.8 years). RESULTS: MIC-1 serum levels independently predicted poor cancer-specific survival with an almost 3-fold higher cancer death rate in patients with serum levels in the highest quartile compared with men with serum levels in the lowest quartile (adjusted hazard ratio, 2.98; 95% confidence interval, 1.82-4.68). Pretreatment MIC-1 levels revealed an even stronger association with disease outcome with an 8-fold higher death rate in the highest compared with the lowest category (adjusted hazard ratio, 7.98; 95% confidence interval, 1.73-36.86). Among patients considered to have localized disease, MIC-1 significantly increased the discriminative capacity between indolent and lethal prostate cancer compared with the established prognostic markers clinical stage, pathologic grade, and prostate-specific antigen level (P = 0.016). A sequence variant in the MIC-1 gene was associated with decreased MIC-1 serum levels (P = 0.002) and decreased prostate cancer mortality (P = 0.003), suggesting a causative role of MIC-1 in prostate cancer prognosis. CONCLUSIONS: Serum MIC-1 concentration is a novel biomarker capable of predicting prostate cancer prognosis.</p>
  •  
8.
  • Brown, David A., et al. (författare)
  • Macrophage Inhibitory Cytokine 1 : A New Prognostic Marker in Prostate Cancer
  • 2009
  • Ingår i: Clinical Cancer Research. - AMER ASSOC CANCER RESEARCH. - 1078-0432 .- 1557-3265. ; 15:21, s. 6658-6664
  • Tidskriftsartikel (refereegranskat)abstract
    • <p>Purpose: High serum levels of macrophage inhibitory cytokine 1 (MIC-1) are strongly associated with metastatic prostate cancer, suggesting MIC-1 is a biomarker for prostate cancer prognosis. Experimental Design: We conducted a prospective cohort study of 1,442 Swedish men with a pathologically verified diagnosis of prostate cancer between 2001 and 2003. Blood was drawn either pretreatment (n = 431) or posttreatment (n = 1,011) and cases were followed for a mean time of 4.9 years (range, 0.1-6.8 years). Results: MIC-1 serum levels independently predicted poor cancer-specific survival with an almost 3-fold higher cancer death rate in patients with serum levels in the highest quartile compared with men with serum levels in the lowest quartile (adjusted hazard ratio, 2.98; 95% confidence interval, 1.82-4.68). Pretreatment MIC-1 levels revealed an even stronger association with disease outcome with an 8-fold higher death rate in the highest compared with the lowest category (adjusted hazard ratio, 7.98; 95% confidence interval, 1.73-36.86). Among patients considered to have localized disease, MIC-1 significantly increased the discriminative capacity between indolent and lethal prostate cancer compared with the established prognostic markers clinical stage, pathologic grade, and prostate-specific antigen level (P = 0.016). A sequence variant in the MIC-1 gene was associated with decreased MIC-1 serum levels (P = 0.002) and decreased prostate cancer mortality (P = 0.003), suggesting a causative role of MIC-1 in prostate cancer prognosis. Conclusions: Serum MIC-1 concentration is a novel biomarker capable of predicting prostate cancer prognosis. (Clin Cancer Res 2009;15(21):6658-64)</p>
  •  
9.
  • Dahlstrom, Lisen Arnheim, et al. (författare)
  • Prospective Seroepidemiologic Study of Human Papillomavirus and Other Risk Factors in Cervical Cancer
  • 2011
  • Ingår i: Cancer Epidemiology Biomarkers & Prevention. - American Association for Cancer Research. - 1538-7755. ; 20:12, s. 2541-2550
  • Tidskriftsartikel (refereegranskat)abstract
    • Background: Several sexually transmitted infections (STI) have been reported to interact with human papillomavirus (HPV) in the etiology of cervical cancer. A large cohort study is required to obtain a both unbiased and stable estimate of their effects. Methods: Four major biobanks in the Nordic Countries containing samples from about 1,000,000 subjects were linked with nation-wide cancer registries. Serum samples from 604 women with invasive cervical cancer (ICC) diagnosed on average 10 years after sampling and 2,980 matched control women were retrieved and analyzed with serology for key STI. Results: Exposure to HPV16 was the strongest risk factor for cervical cancer [ OR = 2.4; 95% confidence interval (CI), 2.0-3.0], particularly for squamous cell carcinoma (OR = 2.9; 95% CI, 2.2-3.7). HPV18 was strongly associated with increased risk for adenocarcinoma (OR = 2.3; 95% CI, 1.3-4.1). Baseline seropositivity for HPV16 did not confer any increased risk for HPV18 DNA-positive cancer and conversely HPV18 seropositivity had no association with HPV16 DNA-positive cancers. HPV6 had no effect on its own (OR = 1.1; 95% CI, 0.9-1.3), but had an antagonistic effect on the risk conferred by HPV16 (P < 0.01). Herpes simplex virus 2 had little or no association (OR = 1.1; 95% CI, 0.8-1.4). Previous exposure to Chlamydia trachomatis, as indicated by serum antibodies, had a strongly increased risk for cervical cancer (OR = 1.9; 95% CI, 1.5-2.3). Conclusions: A large prospective study has assessed the role of different STIs in cervical cancer. Impact: Prospective evidence supports cofactor role of some STI in cervical cancer. Cancer Epidemiol Biomarkers Prev; 20(12); 2541-50. (C) 2011 AACR.
  •  
10.
  • Dimberg, Lina Y., et al. (författare)
  • Stat1 activation attenuates IL-6 induced Stat3 activity but does not alter apoptosis sensitivity in multiple myeloma
  • 2012
  • Ingår i: BMC Cancer. - BioMed Central (BMC). - 1471-2407. ; 12
  • Tidskriftsartikel (refereegranskat)abstract
    • Background: Multiple myeloma (MM) is at present an incurable malignancy, characterized by apoptosis-resistant tumor cells. Interferon (IFN) treatment sensitizes MM cells to Fas-induced apoptosis and is associated with an increased activation of Signal transducer and activator of transcription (Stat)1. The role of Stat1 in MM has not been elucidated, but Stat1 has in several studies been ascribed a pro-apoptotic role. Conversely, IL-6 induction of Stat3 is known to confer resistance to apoptosis in MM. Methods: To delineate the role of Stat1 in IFN mediated sensitization to apoptosis, sub-lines of the U-266-1970 MM cell line with a stable expression of the active mutant Stat1C were utilized. The influence of Stat1C constitutive transcriptional activation on endogenous Stat3 expression and activation, and the expression of apoptosis-related genes were analyzed. To determine whether Stat1 alone would be an important determinant in sensitizing MM cells to apoptosis, the U-266-1970-Stat1C cell line and control cells were exposed to high throughput compound screening (HTS). Results: To explore the role of Stat1 in IFN mediated apoptosis sensitization of MM, we established sublines of the MM cell line U-266-1970 constitutively expressing the active mutant Stat1C. We found that constitutive nuclear localization and transcriptional activity of Stat1 was associated with an attenuation of IL-6-induced Stat3 activation and up-regulation of mRNA for the pro-apoptotic Bcl-2 protein family genes Harakiri, the short form of Mcl-1 and Noxa. However, Stat1 activation alone was not sufficient to sensitize cells to Fas-induced apoptosis. In a screening of > 3000 compounds including bortezomib, dexamethasone, etoposide, suberoylanilide hydroxamic acid (SAHA), geldanamycin (17-AAG), doxorubicin and thalidomide, we found that the drug response and IC50 in cells constitutively expressing active Stat1 was mainly unaltered. Conclusion: We conclude that Stat1 alters IL-6 induced Stat3 activity and the expression of pro-apoptotic genes. However, this shift alone is not sufficient to alter apoptosis sensitivity in MM cells, suggesting that Stat1 independent pathways are operative in IFN mediated apoptosis sensitization.
Skapa referenser, mejla, bekava och länka
Åtkomst
fritt online (42)
Typ av publikation
tidskriftsartikel (238)
konferensbidrag (29)
annan publikation (15)
doktorsavhandling (9)
bokkapitel (6)
rapport (5)
visa fler...
samlingsverk (redaktörskap) (2)
forskningsöversikt (1)
licentiatavhandling (1)
visa färre...
Typ av innehåll
refereegranskat (253)
övrigt vetenskapligt (75)
populärvet., debatt m.m. (5)
Författare/redaktör
Wiklund, Fredrik (175)
Grönberg, Henrik (85)
Xu, Jianfeng (67)
Adami, Hans Olov (55)
Stattin, Pär, (53)
Gronberg, Henrik (45)
visa fler...
Bälter, Katarina (44)
Isaacs, William B (42)
Zheng, S Lilly (33)
Sun, Jielin (33)
Wiklund, Anna-Lena, (30)
Klingvall, Eva (23)
Wiklund, F, (21)
Wiley, Kathleen E (21)
Schleutker, Johanna (20)
Johansson, Jan-Erik (19)
Isaacs, Sarah D (19)
Stanford, Janet L (18)
Duggan, David (18)
Hsu, Fang-Chi (18)
Giles, Graham G (17)
Maier, Christiane (17)
Thibodeau, Stephen N (17)
Adolfsson, Jan (17)
Johansson, Mattias (17)
Kraft, Peter (17)
Carpten, John D (17)
Walsh, Patrick C (17)
Chanock, Stephen J (16)
Wiklund, Urban, (15)
Berndt, Sonja I (15)
Schaid, Daniel J (15)
Kote-Jarai, Zsofia (14)
Öberg, Fredrik, (14)
Jernberg-Wiklund, He ... (14)
Eeles, Rosalind A (13)
Cancel-Tassin, Geral ... (13)
Stattin, Par (13)
Hunter, David J. (13)
Lindström, Sara, (13)
Haiman, Christopher ... (12)
Muir, Kenneth (12)
Travis, Ruth C (12)
Cannon-Albright, Lis ... (12)
Hopper, John L. (12)
Cooney, Kathleen A. (12)
Emanuelsson, Monica (12)
McDonnell, Shannon K (12)
Bonn, Stephanie E, (12)
Lindstrom, Sara (12)
visa färre...
Lärosäte
Umeå universitet (110)
Uppsala universitet (61)
Lunds universitet (39)
Göteborgs universitet (29)
Karolinska Institutet (28)
Mälardalens högskola (21)
visa fler...
Linköpings universitet (13)
Linnéuniversitetet (13)
Örebro universitet (9)
Kungliga Tekniska Högskolan (5)
Luleå tekniska universitet (3)
Stockholms universitet (3)
Chalmers tekniska högskola (2)
Högskolan Kristianstad (1)
Mittuniversitetet (1)
Blekinge Tekniska Högskola (1)
visa färre...
Språk
Engelska (283)
Svenska (5)
Odefinierat språk (3)
Forskningsämne (UKÄ/SCB)
Medicin och hälsovetenskap (172)
Humaniora (31)
Naturvetenskap (25)
Teknik (15)
Samhällsvetenskap (8)

År

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy